ClinicalTrials.gg
RecruitingNCT07230834VIENNAUpdated Aug 5, 2026

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

A Phase 1 interventional study of Pozelimab in Geographic Atrophy (GA), sponsored by Regeneron Pharmaceuticals. Recruiting at 9 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Regeneron Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 131 studies in Geographic Atrophy with a site in United States — 35 open to participants now, 45 under way, 5 of them phase 3. Geographic Atrophy · United States.

Planned enrollment
70th of 107
54 · median 98
Started
2026
with 8 others
Phase 1
16 of 131
3 open now
Primary completion
2028-07
later than 28 of 44 live
Registered
121st of 131
by date

Among the 131 studies in Geographic Atrophy with a site in United States, this one is the 70th largest by planned enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2026, is one of 16 in phase 1, reaches primary completion later than 28 of the 44 other live ones, and was the 121st registered.

Geographic Atrophy

188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.

Browse Geographic Atrophy studies →

Open to participants now

35 of the 131 studies in Geographic Atrophy with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Geographic Atrophy with a site in United States, or all of them as a file.
02

Study summary

This study is researching an experimental drug called pozelimab (called "study drug"). The study is focused on people with a condition where certain parts of the eye's retina stop working over time, which can make it harder to see. This is called geographic atrophy (GA).

The aim of the study is to see how safe and tolerable the study drug is when used as an injection in the eye.

The study is looking at several other research questions, including:

  • What side effects may happen from taking the study drug
  • How much study drug is in the blood and the fluid in the eye at different times
  • Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
03

Conditions studied

  • Geographic Atrophy (GA)

Keywords

  • Age-related Macular Degeneration (AMD)
  • GA secondary to AMD
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Study eye with diagnosis of GA of the macula secondary to AMD, as determined by the investigator
  2. Study eye with total GA area measuring approximately one disc area or greater in size (2.5 mm\^2 or larger) at screening, as determined by the Central Reading Center (CRC), as described in the protocol
  3. Best-Corrected Visual Acuity (BCVA) of 60 letters or worse using the Early Treatment Diabetic Retinopathy Score (ETDRS) charts (Snellen equivalent of \~ ≤20/63) in the study eye at screening and baseline visit

Key Exclusion Criteria:

  1. GA (macular atrophy) in either eye due to causes other than dry AMD
  2. History or current evidence of macular neovascularization and/or retinal exudation in either eye
  3. Concurrent eye disease (elevated Intraocular Pressure (IOP) >25mm Hg, diabetic retinopathy, ocular infections/inflammation)
  4. Prior or current intravitreal (IVT) treatment of any kind for any indication in either the study or fellow eye, except complement inhibitor therapy for GA, as long as last dose was ≥3 months prior to screening
  5. Any prior systemic treatment for dry AMD, except oral supplements or vitamins
  6. History or current use of systemic complement inhibitor therapy

Note: Other protocol-defined Inclusion/ Exclusion criteria apply

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    Part A

    Drug: Pozelimab

  • Experimental
    Part B

    Drug: Pozelimab

Interventions

  • Administered per the protocol

    Also known as: REGN3918

06

What researchers measure

Primary outcomes

  1. Occurrence of ocular Treatment-Emergent Adverse Event (TEAEs) in the study eye

    Part A

    Time frame: Through week 8

  2. Occurrence of ocular TEAEs in the study eye

    Part B

    Time frame: Through week 16

  3. Occurrence of systemic TEAEs

    Part A

    Time frame: Through week 8

  4. Occurrence of systemic TEAEs

    Part B

    Time frame: Through week 16

Secondary outcomes

  1. Concentrations of pozelimab in serum

    Part A

    Time frame: Through week 8

  2. Concentrations of pozelimab in serum

    Part B

    Time frame: Through week 16

  3. Occurrence of Anti-Drug Antibody (ADA) to pozelimab

    Part A

    Time frame: Through week 8

  4. Magnitude of ADA to pozelimab

    Part A

    Time frame: Through week 8

  5. Occurrence of ADA to pozelimab

    Part B

    Time frame: Through week 16

  6. Magnitude of ADA to pozelimab

    Part B

    Time frame: Through week 16

07

Study locations

9 of 9 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jul 2028, 29 months after the start.

Of 13 phase 1 interventional studies under Geographic Atrophy, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Jan 19, 2026
Primary completionEst.
Jul 3, 2028
CompletionEst.
Jul 3, 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230834
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Jan 19, 2026
Primary completion
Jul 3, 2028 (estimated)
Completion
Jul 3, 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@regeneron.com
844-734-6643
Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pozelimab

Start the discussion